| __timestamp | Amgen Inc. | Amicus Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4699000000 | 20717000 |
| Thursday, January 1, 2015 | 4846000000 | 47269000 |
| Friday, January 1, 2016 | 5062000000 | 71151000 |
| Sunday, January 1, 2017 | 4870000000 | 88671000 |
| Monday, January 1, 2018 | 5332000000 | 127200000 |
| Tuesday, January 1, 2019 | 5150000000 | 169861000 |
| Wednesday, January 1, 2020 | 5730000000 | 156407000 |
| Friday, January 1, 2021 | 5368000000 | 192710000 |
| Saturday, January 1, 2022 | 5414000000 | 213041000 |
| Sunday, January 1, 2023 | 6179000000 | 275270000 |
| Monday, January 1, 2024 | 7096000000 |
Infusing magic into the data realm
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Amgen Inc. and Amicus Therapeutics, Inc. have shown contrasting approaches to handling these costs. From 2014 to 2023, Amgen's SG&A expenses have consistently been higher, peaking at approximately $6.2 billion in 2023. In contrast, Amicus Therapeutics, Inc. has maintained a leaner structure, with expenses growing from $20 million in 2014 to $275 million in 2023. This represents a 13-fold increase, highlighting their rapid expansion. Despite Amgen's larger scale, their expenses have grown by only 31% over the same period. This data provides a fascinating insight into how two companies navigate financial management in a dynamic market, with Amgen focusing on scale and Amicus on growth.
Eli Lilly and Company vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Amgen Inc. vs Sanofi
Cost Management Insights: SG&A Expenses for Amgen Inc. and Teva Pharmaceutical Industries Limited
Operational Costs Compared: SG&A Analysis of Amgen Inc. and BioMarin Pharmaceutical Inc.
Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Amgen Inc. or Galapagos NV
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Novavax, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc. Trends and Insights
GSK plc vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Alnylam Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Bausch Health Companies Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Arrowhead Pharmaceuticals, Inc.